Sol-Gel Technologies Cash Flow from Operating Activities 2016-2024 | SLGL
Sol-Gel Technologies cash flow from operating activities from 2016 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
Sol-Gel Technologies Annual Cash Flow Ops
(Millions of US $) |
| 2023 |
$-18 |
| 2022 |
$-9 |
| 2021 |
$-8 |
| 2020 |
$-25 |
| 2019 |
$-23 |
| 2018 |
$-23 |
| 2017 |
$-24 |
| 2016 |
$-18 |
| 2015 |
$-8 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.016B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
